Previous 10 | Next 10 |
home / stock / telo:cc / telo:cc news
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the " Company " or " TELO ") announces that it has entered into an agreement with Leede Jones Gable Inc. (" Leede ") to compensate Leede for strategic advice provided in connection with the Com...
Toronto, Ontario--(Newsfile Corp. - June 14, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the " Company " or " Telo ") announces that it has closed its previously announced non-brokered private placement (" Offering ") of units (the " Units "). The Company issued a total of 11,335...
Toronto, Ontario--(Newsfile Corp. - June 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") presented the results of its latest study on Friday June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunct...
Toronto, Ontario--(Newsfile Corp. - June 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the " Company " or " TELO ") is pleased to announce that it has increased the size of its previously announced non-brokered private placement (" Offering ") from up to $2 million in proceeds to ...
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented ear...
Toronto, Ontario--(Newsfile Corp. - May 19, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the " Company " or " Telo ") is pleased to announce a non-brokered private placement of units (" Units ") at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the " Offering "). Each...
Toronto, Ontario--(Newsfile Corp. - May 4, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is pleased to announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be publish...
Toronto, Ontario--(Newsfile Corp. - April 13, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is excited to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) 2023 annual meeting was accepted for presentation and will b...
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is pleased to announce that it has recently completed the interim assessment of its systems and protocols for ISO 15189 certification with over 90% compliance. ISO...
Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is excited to announce the launch of our inaugural multiple myeloma clinical advisory board ("MM CAB"). The advisory group met at the American Society of Hemato...
News, Short Squeeze, Breakout and More Instantly...
Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncolo...
Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, u...
Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), ( the "Company" or "Telo"), a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology, is thrilled t...